Investment Analysts’ Recent Ratings Updates for Natera (NTRA)

A number of research firms have changed their ratings and price targets for Natera (NASDAQ: NTRA):

• 9/25/2026 – Natera had its price target raised by Royal Bank Of Canada from $350.00 to $460.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Natera had its price target raised by UBS Group AG from $290.00 to $435.00. They now have a “buy” rating on the stock.
• 9/8/2026 – Natera is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $385.00 price target on the stock.
• 9/8/2026 – Natera was upgraded by Royal Bank Of Canada from “outperform” to “buy”.
• 9/8/2026 – Natera is now covered by Rothschild & Co Redburn. They set a “buy” rating and a $385.00 price target on the stock.
• 8/13/2026 – Natera had its price target raised by Citigroup Inc. from $315.00 to $365.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Natera had its price target raised by Stephens from $305.00 to $350.00. They now have an “overweight” rating on the stock.
• 8/12/2026 – Natera had its price target raised by Guggenheim from $290.00 to $360.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Natera was upgraded by Zacks Research from “strong sell” to “hold”.
• 8/12/2026 – Natera had its price target raised by Piper Sandler from $249.00 to $363.50. They now have an “overweight” rating on the stock.
• 8/10/2026 – Natera had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $355.00 price target on the stock.
• 8/7/2026 – Natera had its price target raised by TD Cowen from $325.00 to $340.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Natera had its price target raised by Royal Bank Of Canada from $275.00 to $350.00. They now have an “outperform” rating on the stock.
• 8/7/2026 – Natera was given a new $348.00 price target by Robert W. Baird.
• 8/7/2026 – Natera was given a new $375.00 price target by Canaccord Genuity Group Inc..
• 8/7/2026 – Natera had its price target raised by Wells Fargo & Company from $220.00 to $284.00. They now have an “equal weight” rating on the stock.
• 8/7/2026 – Natera had its price target raised by Citigroup Inc. from $300.00 to $315.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Natera had its price target raised by BTIG Research from $290.00 to $320.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Natera was given a new $330.00 price target by Leerink Partners.
• 8/7/2026 – Natera had its “overweight” rating reaffirmed by Barclays PLC. They now have a $340.00 price target on the stock.
• 8/7/2026 – Natera had its price target raised by JPMorgan Chase & Co. from $315.00 to $360.00. They now have an “overweight” rating on the stock.

Insider Transactions at Natera

In related news, CEO Steven Chapman sold 3,580 shares of the firm’s stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $254.07, for a total value of $909,570.60. Following the transaction, the chief executive officer owned 102,973 shares in the company, valued at $26,162,350.11. This trade represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Michael Brophy sold 2,419 shares of Natera stock in a transaction dated Tuesday, July 28th. The stock was sold at an average price of $253.96, for a total value of $614,329.24. Following the completion of the sale, the chief financial officer owned 54,295 shares of the company’s stock, valued at approximately $13,788,758.20. The trade was a 4.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 51,712 shares of company stock worth $15,169,034 in the last ninety days. 5.05% of the stock is currently owned by insiders.

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to assess genetic and disease-related risks. The company uses technologies including cell-free DNA analysis and next-generation sequencing to support clinical decision-making in reproductive health, oncology and organ transplantation.

Its reproductive health offerings include Panorama, a noninvasive prenatal test that screens for certain chromosomal conditions, and Horizon, a carrier screening test that evaluates whether prospective parents carry genetic variants associated with inherited disorders.